$49.00
3.37.22%
At close: -
$49.51
0.511.04%
After Hours: Nov 22, 6:19 PM EDT
Comments
Loading...
Halozyme Therapeutics (NASDAQ:HALO) Stock, Guidance And Forecast
Companies issue guidance, or expectations of future EPS and revenue, so investors have a sense of how much money a company will make in a future period.
Data brought to you by Benzinga APIs
FAQ
What is the most recent guidance for Halozyme Therapeutics (HALO)?
The most recent guidance for Halozyme Therapeutics (HALO) was reported on October 31, 2024 for the full year 2024. The company provided earnings per share guidance in the range of $4.00 to $4.20, compared to the estimated EPS of $3.96. Additionally, Halozyme Therapeutics forecasted revenue between $0.97B and $1.02B for the quarter.
Browse guidance and forecast on all stocks.